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DThese codes are mainly used for billing purposes, and
therefore the definition of the procedures may not be as
reliable. To minimize variations in coding between
institutions, we therefore decided to use RACHS scores to
create the procedure groups. A limitation of this approach
is that cardiac surgical procedures without an assigned
RACHS score were not included in the study. It is
plausible that some of these procedures may have been
associated with a higher or lower incidence of chylothorax.
Information on reoperations, which intuitively would
seem to be potentially associated with a higher risk of
chylothorax, is not available in the PHIS database.
Despite these limitations, the use of a multi-institution
national database allows the compilation of multiple and
diverse cases to determine risk factors and treatment
strategies that would otherwise be impossible to analyze.
In conclusion, acknowledging the limitations of this
study, chylothorax is a significant problem in pediatric
cardiac surgery and is associated with increased mortality,
cost, and hospital stay. Further studies are warranted to
develop strategies for prevention and treatment of this
disease, especially among the group of patients at highest
risk, such as neonates undergoing complex congenital
cardiac procedures.References
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Dr Glen Van Arsdell (Toronto, Ontario, Canada). I have no
disclosures that relate to this presentation.
In this report of nearly 80,000 patients undergoing congenital
heart surgery, Mery and colleagues have shown that not only is
chylothorax frustrating for caregivers, it can also be lethal.
Most of the findings are consistent with what we would expect.
Somewhat surprisingly, however, there was a lower incidence than
previously identified in single-institution case series, and therewas
a difference in incidence between institutions. Perhaps there is also
an increasing incidence with time. Of course, we would like to
know why these findings might be.
Dr Mery, bearing in mind the limitations of an administrative
database, and they are substantial, did you look for and were
you able to identify clues as to practice patterns that might help
explain a different incidence between institutions? The fact that
surgeon volume did not impact the incidence of chylothorax, but
institution volume did, suggests that institution protocols could
be conceivably more important than individual surgical technique.
For example, protocol findings might be differing age of treatment
between institutions for the same RACHS classification, or, for
example, a higher use of low–molecular weight heparin, which
might impact the thrombotic risk for chylothorax. Was there an
analysis that you performed in this regard that had either positive
or negative results?
Dr Mery. Thank you for your very insightful comments.
Indeed, some of the findings of this study were somewhat
surprising.
One of the problems with using administrative databases
that are based on ICD-9-CM codes is that you can actually
underestimate the incidence of disease. There are some studies
that have compared the incidences of reported diseases such as
bronchiolitis and aspergillosis in an administrative database with
actual clinical data and have found that the real incidence of
disease may be between 10% and 40% higher than that reported
in the administrative database. From this, I would say that the chy-
lothorax incidence is at least 2.8% and could actually be higher.
As far as the relationship between the incidence of chylothorax
and hospital volume goes, I totally agree with you. Some possible
explanations could be due to differences in protocols for enteral
feeding, patient selection, and postoperative patient management.
I submit that even surgical technique may play a role, even though
it may not be related to surgeon volume itself. Surgeons that
operate in hospitals that have higher volume may have different
techniques than surgeons that do not; obviously something we
cannot prove. Part of the explanation may also have to do with
the way the data were analyzed. If you actually look at the hospital
volume quartiles that we used, the highest hospital volume quartile
included only 5 hospitals, compared with 19 hospitals that
were included on the first quartile, so the data may be more
heterogeneous for the lower volume hospitals.
We did not look at the use of low–molecular weight heparin.
Dr Van Arsdell. I suspect there may be a few broad large
categories, such as drug usage or age, that you could see whetherrdiovascular Surgery c Volume 147, Number 2 685
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interesting analysis to perform.
In our own database, about 15% of patients did not fit into the
RACHS classification. These patients had a similar mortality to
RACHS 5 and 6. Were you able to account for all patients who
had heart surgery, even if they did not fit into a RACHS
classification? And if not, might that be some of the explanation
as to why there was a relatively low incidence of chylothorax?
DrMery. That is a very good point. By definition, we only took
patients who had a RACHS-associated procedure; that is how we
identified patients in the database who had cardiac surgery. We
could definitely be missing patients with a different incidence of
chylothorax. One of the limitations of the PHIS database is that
it uses ICD-9-CM diagnosis and procedure codes, and these can
be unreliable. For example, we do not know which patients had
Norwood procedures, because there is no ICD-9-CM procedure
code for a Norwood. It is instead a combination of procedure codes
for an atrial septectomy, an aortic arch reconstruction, and some
type of systemic-to-pulmonary shunt. That is why we relied on
the RACHS scores that are reported on this database, rather than
using particular procedure codes. We did not perform any analyses
comparing drug usage or age between institutions, but I agree that
it would be an interesting analysis.
Dr Van Arsdell. And my last question, you found this
increasing incidence of chylothorax with time. Similar to the first
question, did you look for practice pattern changes, such as billable
feedings, which you alluded to, that might suggest protocols that
would drive this change?
Before you answer that, congratulations on a great presentation
and a very nice manuscript as well. And thank you for stimulating
this discussion on an important topic.
Dr Mery. Thank you very much. We did not look at difference
in practice patterns. It may be true that the increase in incidence
that we are seeing might just be an increase in detection and
reporting, because there has been increased awareness of this
problem during the last few years. It is interesting, though, that
single-institution studies have also shown an increasing incidence
with time. The incidence in the 1970s and 1980s was reported to be
between 0.5% and 1%, and now it is much higher. It is unclear
whether that is a result of increased awareness, changes in enteral
feeding patterns, or actual increasing incidence.
Dr J. William Gaynor (Philadelphia, Pa). I have no
disclosures. I just want to mention a novel therapy that we have
been using recently that was developed by Dr Max Itkin, one of
our interventional radiologists, that has been very successful in
many cases. He uses percutaneous cannulation of the cisterna chyli
and then performs a lymphangiogram. He can identify anatomic
variations. He can sometimes identify a leaky vessel. And then
he embolizes with the thoracic duct or the lead. This has been
done in infants as young as 1 month, and it has been very, very
successful. We go to it much quicker than we used to sticking
with feeds and chest tube drainage and going in. We have all686 The Journal of Thoracic and Cardiovascular Surghad the frustration of trying to go in with somebody with a
chylothorax, and the lymph seems to be coming from everywhere
and you cannot identify a single leak. Obviously, this needs to be
replicated. He has published several papers on the technique, and it
has been very successful. Thank you, I enjoyed your presentation.
Dr Mery. I agree. Techniques like these may play a role in
trying to decrease the amount of time that goes from the diagnosis
of chylothorax to successful treatment. Our data do not allow us to
know when the diagnosis of chylothorax was made during the
admission, but the surgical procedures were performed a median
of 18 days after cardiac surgery. So there was good lapse of time
where conservative management was used, and these techniques
could potentially minimize that time.
Dr Peter Manning (St Louis, Mo). I think this is a good
example of a study where you have to be careful about drawing
conclusions about cause and effect versus association. You have
done a good job of that. As I think you said on your first slide,
the etiology of chylothorax can be multifactorial. Most of these
cases are not major thoracic duct injuries, but the thrombosis of
central veins or high central venous pressures are really important
factors, and consideration of these issues must be factored into the
evaluation and management of chylothorax.
My question is, do you think chylothorax itself is the morbid
entity, or is it a marker of very complex patients who have high
central venous pressures and have intravenous lines for a long
time that thrombose the superior vena cava?
Dr Mery. I think you are totally correct, and that is the difficult
part of database studies like this, because we cannot really assess
causation, just association. It is true, the development of
chylothorax may just be a proxy for multiple comorbidities that
are both increasing the risk of chylothorax in these patients and
at the same time increasing the risk of morbidity and mortality.
Dr Pedro J. Del Nido (Boston, Mass). Following up on that,
I think the institutional differences argue against an anatomic
factor. Presumably, these are the same children who are undergo-
ing surgery in one institution versus another. So I think one would
argue more for practice patterns as playing a significant role.
DrOsama Eltayeb (Tulsa, Okla). In your study, did you look at
the incidence of Chylothorax in early repair of tetralogy of Fallot?
Most of the centers have moved toward early repair; does that
increase the incidence of chylothorax? If not, maybe it is for the
panel to comment whether there is any increase of chylothorax
incidence after early repair of tetralogy.
DrMery.One of the problems with this database is that we rely
on very simplified codes, sowe cannot really obtain a lot of clinical
data. For example, trying to differentiate between Glenn and
Fontan procedures is impossible, because they are both coded as
cavopulmonary anastomoses unless the Fontan is a lateral
tunnel procedure, which would be coded as an atriopulmonary
anastomosis. So unfortunately, we do not have details in terms
of the particulars of procedures because of the nature of the
PHIS database.ery c February 2014
